u/copay_card_cc

Same experience with the appetite effect being flatter across the week rather than front-loaded.

stretching the interval is not the same as reducing the dose

Small correction, kindly meant: that is a range rather than a regain. Weight moves day to day in everybody.

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

Are you quoting advice from before the compounded arrangements changed?

Adding the quickest step — ask the pharmacist to check the wholesaler.

a streamlined authority code is not the same as a general listing

the shortage listing has an expected resolution date on it

Agreed — the database rather than the coverage, every time.

the four-week step schedule is the label, not folklore

Small fix — archiving happens at a year, not at six months. It is in the published policy.

Have you taken this to modmail first?

the ranking formula is published, go and read it

How many weeks between the two measurements?

Cosigning on baseline. The panel I regret most is the one I did not take before starting.

Added ApoB to the panel after a thread here. It told me something the standard lipid panel had been hiding.

Same experience with the appetite effect being flatter across the week rather than front-loaded.

the trend line matters more than any single value

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

Week 42 was the first time the scale moved after a five-week stall. I changed nothing in that window.

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

a lot of people plateau nicely at 10mg and never need 15

Research-use-only material is not approved for human use.

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

Wrote down what maintenance would look like at about week 46, before I needed it. Having decided in advance made the transition boring.

Same lab as the previous draw?

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

zepbound and mounjaro are the same compound with different labels

How to make a panel worth comparing, which is most of the value people leave on the table.

Standardise the conditions: same lab, same fasting state, same rough time of day, same point in the week, similar hydration. Take a baseline before you change anything. Repeat any surprising value before acting on it. Change one thing at a time if you want to attribute anything to it.

Do that and a year of panels is a trend. Skip it and a year of panels is a collection of unrelated mornings, which is what most of the alarmed posts here are actually describing.

Personal importation provisions exist, are narrow, and carry conditions. Any summary of them here should be checked against the current official wording rather than a forum post.

2.5 is the starter dose and it is not meant to be the dose that works

This. The step interval is a floor, and reading it as a timetable is the most expensive mistake in the thread.

if 7.5 is working, 10 is not automatically better

Sulphur burps for the first eight days after each step, then nothing.

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

Assumed the New Zealand position applied here. It does not, and someone corrected me politely with the actual source.

Is the goal you set at the start still the goal?

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

Push back: that is not a plateau, that is maintenance. You have arrived and you are describing it as a failure.

the first person to notice was me, months after it started

Yes — the shortage database is the source. The news coverage of it is downstream and usually a week behind.